194 related articles for article (PubMed ID: 32027741)
1. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Pedrosa F; Coustan-Smith E; Zhou Y; Cheng C; Pedrosa A; Lins MM; Pedrosa M; Lucena-Silva N; Ramos AML; Vinhas E; Rivera GK; Campana D; Ribeiro RC
Blood; 2020 Apr; 135(17):1458-1466. PubMed ID: 32027741
[TBL] [Abstract][Full Text] [Related]
2. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
3. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
4. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
[TBL] [Abstract][Full Text] [Related]
5. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
Sandlund JT; Pui CH; Zhou Y; Behm FG; Onciu M; Razzouk BI; Hijiya N; Campana D; Hudson MM; Ribeiro RC
Leukemia; 2009 Jun; 23(6):1127-30. PubMed ID: 19194463
[TBL] [Abstract][Full Text] [Related]
7. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
8. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
10. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
11. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
[TBL] [Abstract][Full Text] [Related]
12. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Attarbaschi A; Mann G; Zimmermann M; Bader P; Barisone E; Basso G; Biondi A; Cario G; Cazzaniga G; Colombini A; Flotho C; Kuhlen M; Lang P; Lauten M; Linderkamp C; Locatelli F; Lo Nigro L; Möricke A; Niggli F; Panzer-Grümayer R; Parasole R; Peters C; Caterina Putti M; Rizzari C; Suttorp M; Valsecchi MG; Conter V; Schrappe M;
Leukemia; 2020 Jun; 34(6):1694-1700. PubMed ID: 31806872
[No Abstract] [Full Text] [Related]
13. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
14. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
15. [Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
Derwich K; Kaczmarek-Kanold M; Wachowiak J; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Jackowska T; Kołtan A; Cwiklińska M; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A
Przegl Lek; 2004; 61 Suppl 2():49-52. PubMed ID: 15686046
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Juszczak K; Armata J; Balcerska A; Balwierz W; Bubała H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Lukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sońta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E
Wiad Lek; 1998; 51 Suppl 4():25-32. PubMed ID: 10731940
[TBL] [Abstract][Full Text] [Related]
17. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
18. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
19. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
